- Home
- CVKD
as 10-24-2025 3:56pm EST
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 27.0M | IPO Year: | 2023 |
| Target Price: | $32.00 | AVG Volume (30 days): | 25.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.74 - $22.90 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cadrenal Therapeutics Inc. (CVKD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pham Quang X | CVKD | CEO and Chairman | Oct 13 '25 | Sell | $14.15 | 1,800 | $25,470.00 | 198,533 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 13 '25 | Sell | $14.07 | 1,800 | $25,326.00 | 13,533 | |
| Pham Quang X | CVKD | CEO and Chairman | Oct 9 '25 | Sell | $14.02 | 1,800 | $25,236.00 | 198,533 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 9 '25 | Sell | $13.99 | 1,693 | $23,685.07 | 13,533 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 6 '25 | Sell | $13.99 | 107 | $1,496.93 | 13,533 | |
| Pham Quang X | CVKD | CEO and Chairman | Oct 1 '25 | Sell | $14.01 | 881 | $12,342.81 | 198,533 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 1 '25 | Sell | $13.99 | 1,700 | $23,783.00 | 13,533 | |
| Pham Quang X | CVKD | CEO and Chairman | Sep 29 '25 | Sell | $14.01 | 419 | $5,870.19 | 198,533 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Sep 29 '25 | Sell | $14.00 | 100 | $1,400.00 | 13,533 |
Latest Cadrenal Therapeutics Inc. News
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
Business Wire
4 months ago
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
Business Wire
5 months ago
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
Zacks Small Cap Research
5 months ago
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin…
Business Wire
5 months ago
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
Business Wire
6 months ago
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
Simply Wall St.
7 months ago
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?
Business Wire
7 months ago
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Zacks Small Cap Research
7 months ago
CVKD: Preparing for Phase 3 Trial of Tecarfarin…
Compare CVKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.